NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital appoints Samit Hirawat, M.D., as Strategic Medical Advisor to strengthen Jeito’s leadership in driving innovations for patient benefit
Samit Hirawat, M.D., brings over 25 years of senior leadership and clinical development experience at top-tier international pharmaceutical groups, including Novartis and Bristol Myers Squibb, further enhancing Jeito’s strategic capabilities. His expertise will...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Jeito Capital Makes Significant Investment in the Second Closing of Alveus Therapeutics’ Oversubscribed Series A, Bringing Total Financing to $197 Million
Proceeds from the financing will advance the Phase 2 clinical development of Alveus’ lead program...
Jeito Capital promotes Ksenija Pavletic to General Partner
Paris, France, October 15th, 2025 – Jeito Capital (“Jeito”), a leading global independent private...
Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs
Investment will support Odyssey’s portfolio of clinical and preclinical medicines designed to...
Jeito Capital appoints Pascal Touchon as Operating Partner
Pascal Touchon will reinforce Jeito's expertise by bringing over 35 years of global experience in...
Jeito Capital Leads a USD 65 million Financing in ReproNovo to Develop Transformational Treatments in Reproductive Medicine and Women’s Health
Proceeds from the financing will advance ReproNovo’s lead candidates RPN-001 (leflutrozole) and...
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.